New Director Elected to California Healthcare Institute Board
The California Healthcare Institute (CHI) today announced that Michael A. Friedman, M.D., president and chief executive officer of City of Hope, a leading cancer research, treatment and education center, was elected to its board of directors. CHI is a non-profit public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.
“Dr. Friedman’s experience in the public and private sectors, as a physician, researcher and executive bring a new dimension to CHI’s board,” said David Gollaher, Ph.D., CHI’s president and CEO. “The next Congress and administration will face enormous financial challenges, and our industry must find ways to work with government to preserve incentives for innovation, even as legislators try to rein in healthcare spending. Dr. Friedman’s experience at the intersection of life sciences and government will be extremely valuable.”
City of Hope is one of just 41 Comprehensive Cancer Centers, the highest designation bestowed by the National Cancer Institute and a recognition of excellence in cancer treatment, research, prevention and education. Located in Duarte, Calif., just northeast of Los Angeles, City of Hope is also a founding member of the National Comprehensive Cancer Network, an alliance of top cancer centers that defines and sets standards for cancer care nationally. The organization maintains one of the largest cancer programs in California and maintains prostate, breast and musculoskeletal cancer programs that are among the largest in the state. Its stem cell transplant program is one of the largest and most successful in the nation.
Prior to joining City of Hope, Friedman was senior vice president of research and development, medical and public policy, for Pharmacia Corporation. In addition, he served as chief medical officer for biomedical preparedness at the Pharmaceutical Research and Manufacturers of America following the events of September 11, 2001. Friedman had previously served as U.S. Food and Drug Administration (FDA) deputy commissioner and was tapped by the Clinton administration to serve as acting commissioner of the agency. He helped to streamline the FDA’s review and approval process and provided oversight of evaluations for drugs, biologics, medical devices and food ingredients.
In 1983, Friedman joined the Division of Cancer Treatment at the National Cancer Institute (NCI), and went on to become the associate director of the division’s Cancer Therapy Evaluation Program. Before joining the NCI, Friedman spent nearly a decade at the University of California at San Francisco, serving as associate professor of medicine, and interim director of the Cancer Research Institute.
Friedman has received numerous commendations, including the Surgeon General’s Medallion in 1999. He received his Bachelor of Arts degree, magna cum laude, from Tulane University and a Doctorate in Medicine from the University of Texas. He completed postdoctoral training at Stanford University and the NCI, and is board certified in internal medicine and medical oncology.
CHI represents more than 250 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s Web site is www.chi.org.